A National Institutes of Health study is currently under way that could revolutionize the treatment of asthma, a disease that affects approximately 20 million Americans.
It turns out that there may be a very direct relationship between asthma and the presence of bacteria in the lungs. As a result, a new treatment protocol for asthma may be on the horizon.
The $7.5 million asthma study being conducted by National Jewish Medical and Research Center --one of the country’s premiere centers for respiratory medicine -- will enroll 126 asthma patients from around the U.S. to examine the relationship between asthma and bacteria, and its response to treatment with antibacterial agents.
The study was inspired by a severely debilitated asthma patient who was treated with antibacterial agents when a lung biopsy revealed the presence of bacteria. Her health underwent such a dramatic reversal that she has since run a sprint-distance triathlon and a 10K race!
This might explain why asthma sufferers who use Mesosilver® colloidal silver, which is a natural antibacterial agent, report such excellent results and dramatic improvement in their asthma symptoms.
Not all asthma patients show the presence of bacteria, and not everyone with the bacteria has asthma, but there is a hypothesis that it may be an interaction between allergens and the bacteria – along with a possible genetic predisposition and a certain sequence of exposure – that triggers asthma.
There is even a chance that that treating bacterial infections immediately when they occur could prevent asthma altogether.
The study is also investigating a new method of identifying lung bacteria to replace the highly uncomfortable bronchoscopy, which requires patient sedation.
Those interested in learning more about the study may call 303-398-1443.
For more information about asthma and Mesosilver colloidal silver.
Click to order Mesosilver or call 1-800-390-5839.